Thymalin

What it is

Thymalin is a mixture of short peptides originally extracted from the thymus gland of calves. It is not a single defined peptide, and many research-chemical products sold under the name are synthetic or semi-synthetic versions, so contents can differ. It is registered as a medicine in Russia and some neighbouring countries, but it is not licensed in the UK, US or EU.

Almost all the evidence comes from the group around Vladimir Khavinson in St Petersburg, who developed it and have published most of the human data. Western replication is limited. That does not mean the findings are false, but it does mean you should treat the strong ageing claims with caution.

History

Developed in the 1970s in the Soviet Union by Vladimir Khavinson and Vladimir Morozov at what became the St Petersburg Institute of Bioregulation and Gerontology, and used there as an immune-modulating drug for decades. Khavinson later popularised the idea of short peptide bioregulators for ageing, which led to Epitalon (Epithalon) and others. Roughly 50 years old as a drug in Russia.

How it works

The proposed mechanism is that thymic peptides help immature T-cells mature and rebalance immune function, particularly in older people whose thymus has shrunk. Some Russian studies report effects on immune cell counts and on markers of ageing. The details of how exactly it works are less well established than for Western-researched immune peptides like thymosin alpha-1.

Dosage

• In Russian clinical practice, courses are typically around 5-10 mg per day for roughly 5-10 days, and repeated once or twice a year. Check primary sources for the exact regimens, as this is a summary.
• Community use follows the same short-course pattern: a short burst, then months off, rather than continuous use.
• There is no Western trial-derived dose.

How it is taken

• Russian protocols use intramuscular injection. People using research-grade vials often inject subcutaneously with a 29-31G insulin syringe.
• Rotate sites. Courses are short, so you will be injecting daily for a week or so only.

How to reconstitute

• For a 10 mg vial, adding 1 ml of bacteriostatic water gives 10 mg/ml. On a 1 ml (100-unit) insulin syringe, 50 units (0.5 ml) is 5 mg and 10 units (0.1 ml) is 1 mg.
• For a 20 mg vial, adding 2 ml gives 10 mg/ml, with the same unit maths.
• Add water slowly down the vial wall, swirl gently, and do not shake. A product that is a mixture may look slightly less crisp than a single synthetic peptide.

How it should arrive

A sealed glass vial with white to off-white lyophilised powder.

How it should look once reconstituted

A clear to very slightly hazy, colourless solution. Heavy cloudiness or particles are a red flag.

What to expect, and when

• Russian studies describe immune markers shifting during or shortly after a 5-10 day course.
• Reported effects on general wellbeing or ageing-related measures were measured over months or years, mostly in the same small research groups.
• Do not expect an obvious subjective effect.

Side effects

• Generally reported as well tolerated in the Russian literature.
• Injection-site pain, redness or swelling.
• Allergic reactions are possible, especially with products derived from animal tissue.
• Mild fever or fatigue reported occasionally.

Risks

• Evidence is mostly from one research group, which is not the same as independent confirmation.
• Animal-derived thymic extracts carry a theoretical risk of allergic reaction and, with poor sourcing, contamination. Synthetic-labelled products may or may not match the original.
• Immune modulators are not right for everyone. If you have an autoimmune condition, an organ transplant, or are on immunosuppressants, do not use it without medical advice.
• Not licensed in the UK, so what you are buying is an unregulated product.
• Quality and composition are unverifiable on the grey market.

Potential gains

• In Russian studies, improved immune cell measures and reduced infection rates in older and immunocompromised patients.
• Khavinson-group follow-up reports describe lower mortality in older people given repeated thymic peptide courses. These were not blinded randomised trials in the Western sense, so they cannot be treated as proof.
• No strong independent evidence for ageing benefits.

Other useful information

If you want a thymic peptide with more Western research behind it, thymosin alpha-1 is the better-studied option and has been approved as a medicine in several countries. Thymalin is best understood as a historical Russian drug with a loyal following and limited outside validation.